Part 1 | Genetic Variation Implicates Plasma Angiopoietin-2 in The Development Of Acute Kidney Injury Sub-phenotypes
Mar 03, 2022
Pavan K. Bhatraju1,2*, Max Cohen1, Ryan J. Nagao3,4, Eric D. Morrell1, Susanna Kosamo1, Xin-Ya Chai1, Robin Nance5, Victoria Dmyterko1, Joseph Delaney5, Jason D. Christie6, Kathleen D. Liu7, Carmen Mikacenic1, Sina A. Gharib1, W. Conrad Liles8, Ying Zheng3,4, David C. Christiani9,10, Jonathan Himmelfarb2 and Mark M. Wurfel1,2
Abstract
Background: We previously identified two acute kidney injury (AKI) sub-phenotypes (AKI-SP1 and AKI-SP2) with different risks of poor clinical outcomes and responses to vasopressor therapy. Plasma biomarkers of endothelial dysfunction (tumor necrosis factor receptor-1, angiopoietin-1, and 2) differentiated the AKI sub-phenotypes.
However, it is unknown whether these biomarkers are simply markers or causal mediators in the development of AKI sub-phenotypes.
Methods: We tested for associations between single-nucleotide polymorphisms within the Angiopoietin-1, Angiopoietin-2, and Tumor Necrosis Factor Receptor 1A genes and AKI- SP2 in 421 critically ill subjects of European ancestry. Top-performing single-nucleotide polymorphisms (FDR < 0.05) were tested for cis-biomarker expression and whether genetic risk for AKI-SP2 is mediated through circulating biomarkers. We also completed in vitro studies using human kidney microvascular endothelial cells. Finally, we calculated the renal clearance of plasma biomarkers using 20 different timed urine collections.
Results: A genetic variant, rs2920656C > T, near ANGPT2 was associated with reduced risk of AKI-SP2 (odds ratio, 0.45; 95% CI, 0.31–0.66; adjusted FDR = 0.003) and decreased plasma angiopoietin-2 (p = 0.002). Causal inference analysis showed that for each minor allele (T) the risk of developing AKI-SP2 decreases by 16%. Plasma angiopoietin-2 mediated 41.5% of the rs2920656 related risk for AKI-SP2. Human kidney microvascular endothelial cells carrying the T allele of rs2920656 produced numerically lower levels of angiopoietin-2 although this was not statistically significant (p = 0.07). Finally, analyses demonstrated that angiopoietin-2 is minimally really cleared in critically ill subjects.
Conclusion: Genetic mediation analysis provides supportive evidence that angiopoietin-2 plays a causal role in risk for AKI-SP2.
Keywords: Acute kidney injury, Genetics, Endothelium
For more information please contact: emily.li@wecistanche.com
Cistanche deserticola prevents kidney disease, click here to get the sample
Background
Acute kidney injury (AKI) affects 40–60% of patients ad- mitted to the intensive care unit (ICU) and contributes to poor short- and long-term outcomes. Genetic studies to date have focused on associations between genetic variants and the risk for AKI comparing cases (AKI) to controls (no AKI). However, this framework may be limited because cases of Acute kidney injury are highly heterogeneous with different precipitants and bio-logical profiles. Combining such AKI patients to maximize sample size may result in dilution of genetic statistical signals that might only be present in one pathophysiologically distinct subset of the AKI population. Another limitation is that AKI in critically ill populations is often a complication of serious insults, such as sepsis, surgery, shock, pneumonia, and trauma. The use of controls without the development of Acute kidney injury can be problematic. Controls carrying a high-risk genetic variant might not develop AKI if they do not also experience a similar acute insult as cases, and thus would be classified as non-cases, attenuating any potential association signal. The use of biologically distinct AKI sub-phenotypes in genetic association studies overcomes prior limitations in phenotyping AKI by specifically focusing on the AKI population and by comparing two biologically distinct sub-phenotypes.
We recently identified two AKI sub-phenotypes (AKI- SP1 and AKI-SP2) by applying latent class analysis methodology to a panel of 29 clinical and biomarker variables in two independent critically ill AKI populations. Notably, AKI-SP2 was associated with worse hospital outcomes (e.g. mortality, new dialysis, and 7-day renal non-recovery) compared to AKI-SP1. We next identified these AKI sub-phenotypes in a previously completed multi-center randomized control trial, Vasopressin versus Norepinephrine Infusion in Patients with Septic Shock (VASST). The VASST trial studied whether the choice of vasopressor therapy improved mortality in subjects with septic shock. While the AKI population in the clinical trial had no difference in mortality from vasopressor therapy, AKI-SP1 had a mortality benefit with vasopressin compared to AKI-SP2 having no mortality difference. To our knowledge, this is the first example of identifying treatment responsive AKI sub-groups in the critically ill.
Notably, no single variable was statistically better than the other variables to identify AKI-SP2 (Table 1). In contrast, a three-variable model, using plasma angiopoietin-2 (ANG-2), angiopoietin-1 (ANG-1), and soluble tumor necrosis factor receptor-1 (sTNFR-1), had the optimal predictive performance to differentiate Acute kidney injury sub-phenotypes (C-statistic 0.93). Lower ANG-2, lower sTNFR-1, and higher ANG-1 were associated with a lower risk of AKI-SP2. Studies in animal models of AKI have shown that these plasma biomarkers are involved in the
pathophysiology and severity of AKI. However, it is unknown whether these plasma biomarkers play a causal role in the development of clinical Acute kidney injury sub-phenotypes. The identification of causal markers could inform targets for drug development to prevent or treat the development of Acute kidney injury in the critically ill and could assist in patient risk-stratification.
Genetic mediation analysis is one of several causal inference approaches that can identify the potential mechanism by which an independent variable (e.g., genetic variant) affects the outcome (e.g., AKI sub-phenotypes) via an explanatory mediator (e.g., biomarker of endothelial dysfunction). This approach has been widely applied in clinical data to understand causal mechanisms of dis-ease. We hypothesized that cis-quantitative trait loci (QTLs) in the ANGPT1, ANGPT2, and TNFRSF1A genes influence the development of AKI sub-phenotypes by regulating circulating levels of their respective bio-markers (ANG-1, ANG-2, or sTNFR-1).
Methods
Study populations
We previously reported the identification of AKI sub- phenotypes using a prospectively collected ICU cohort: identification of Single Nucleotide Polymorphisms (SNPs) Predisposing to Altered Acute Lung Injury Risk (iSPAAR). The iSPAAR population is a genome-wide case-control study of the risk of acute respiratory distress syndrome (ARDS) that included patients with and without ARDS. The iSPAAR population included subjects from previously completed randomized control trials and from a prospectively enrolled ICU cohort. Details of the study design for each population enrolled in iSPAAR have been previously described; Albuterol for the Treatment of Acute Lung Injury (ALTA), Fluid and Catheter Treatment Trial (FACTT), Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury (OMEGA)
and Molecular Epidemiology of Acute Respiratory Distress (MEA) at the Massachusetts General Hospital. Within iSPAAR, study enrollment occurred 48 h after ICU admission. At study enrollment DNA and plasma were collected for genotyping and biomarker analysis followed by Acute kidney injury ascertainment. AKI was defined as an increase in serum creatinine (SCr) of ≥0.3 mg/dl or 50% from “baseline” SCr. The baseline SCr was defined as the lowest value prior to study enrollment. AKI was also defined using modified urine output criteria (daily output instead of every 6 h).
To determine the renal clearance of plasma biomarkers, we enrolled a prospective cohort in the Harborview medical and surgical intensive care units, the Critical Illness Acute kidney injury Cohort (CIA). Subjects were eligible for enrollment if they met 2 of 4 systemic inflammatory response syndrome criteria had a clinically-suspected infection and had an indwelling urinary catheter in place. A timed urine collection was completed that lasted at least 2–4h and EDTA plasma samples were collected at the beginning and the end of the timed urine collection. Clearance was calculated using the formula Clearance (X) = U(X) * V/ P(X), where U(X) represents the urine concentration of solute X, V indicates the urine volume over the 2–4-h collection period, and P (X) represents the average plasma concentrations of solute X from the initial and final blood collections.
Genotyping strategy
Genotyping was performed in 421 patients of European ancestry using the Illumina 660 platform (Illumina, San Diego, CA). Genotyped data was quality controlled using a sample call rate filter > 0.97, minor allele frequency (MAF) > 0.01 and SNP call rate > 0.95. After quality control, 238 SNPs ±50 kilobases of ANGPT1, ANGPT2, and TNFRSF1A were found. After linkage disequilibrium (LD) pruning of an r2 of 0.8, 48 SNPs were removed leading to a total of 190 SNPs used in association tests. Imputation was conducted using the 1000 Genomes Project reference panel using IMPUTE2 v2.3.0.
Plasma protein assessment
Plasma and urinary biomarkers were measured using electrochemiluminescent immunoassays (Meso Scale Discovery (MSD), Rockville, MD), as previously described. The blood was collected in EDTA-treated sterile tubes, urine was collected in sterile containers and both were centrifuged immediately. Plasma and urine were then aliquoted and frozen at − 80 °C. The samples were stored for different durations but they were thawed in a single batch and only once for running the biomarker measurements for this study. All biomarker measurements were performed in duplicates at Harbor- view Pulmonary Research Laboratories.
In Silico analyses
To test SNPs for the expression of QTL effects, we queried the Genotype-Tissue Expression (GTEx) Portal.
Cell culture
Human kidney microvascular endothelial cells (HKME Cs) were purified from fetal kidneys after voluntary pregnancy interruptions between 100 and 135 days post-conception. Informed consent for the use of fetal tissues was obtained from patients. We then randomly chose 9 different donors HKMECs, thawed and plated half a million cells in T25 flasks coated with 0.2% gelatin and maintained in EBM-2 basal medium containing 1% antibiotic-antimycotic (Life Technologies), 10% FBS, 100 μg/mL ECGS, 50 μg/mL Heparin, and 20 ng/mL VEGF (R&D), for 48 h till confluency. At 48 h, we purified genomic DNA from the HKMECs and cell supernatants were collected. We successfully genotyped cells from 8 donors.
Statistical analysis
Patient demographic variables are reported as either mean +/−standard deviation or as median and quartiles. First, we used logistic regression to test for an association between the 190 SNPs and the development of AKI-SP2 compared to AKI-SP1 using an additive genetic model (Golden Helix, MT). Our model was ad- used for the following covariates: age, sex, sepsis, and the first five principal components. The Eigenstrat method v4.2 was used to calculate the principal components and the top five were included as covariates. Odds ratios (ORs) are reported with 95% confidence intervals. For the analysis between genetic variants and AKI sub-phenotypes, we corrected for multiple comparisons by using a Benjamini-Hochberg false discovery rate (FDR) threshold < 0.10, which estimates that less than 10% of the associations with an FDR value at or below this level are false positives [31]. In a sensitivity analysis, an imputed genotype was used to identify additional SNPs associated with AKI-SP2.
Second, we used linear regression adjusting for age, sex, and sepsis to determine associations between top-performing SNPs and log2 transformed biomarker concentrations. Third, we completed a causal inference analysis to test the association between genetic variants and AKI-SP2 and the potential mediation of the association by plasma biomarker concentrations. The mediation analysis was performed using the non-linear implementation of structural equation modeling implemented in the mediation package for STATA [32, 33]. Additional details of the causal inference analysis are provided in the online supplement. Fourth, we determined associations between genetic variants and AKI severity, measured by maximum serum creatinine, via logistic regression. Additional details of materials and methods are provided in the online supplement. In the analysis, we evaluated 190 SNPs and used a conservative p-value of 0.05/190 =2.6 × 10− 4. Given that approximately 40% of ICU patients develop AKI, and an expected control (AKI- SP1) to case (AKI-SP2) ratio of 1.5, an expected sample size of 421, and a MAF of at least 0.30, we will have 81% power to detect a relative risk of 1.5 or greater [34]. Analyses were completed using STATA (Version 15) and Goldenhelix (Version 4.0). All studies were approved by the Human Subjects Division at the University of Washington. Written informed consent was obtained from all subjects enrolled.
Results
Characteristics of populations Of the 425 patients from the validation cohort in our previous work, 421 had genotyping data available. Demographics and baseline clinical characteristics are described in Table 1. All subjects were of European ancestry. A total of 267 (63%) were classified as AKI-SP1 and 154 (37%) as AKI-SP2. Subjects who developed AKI-SP2 had higher illness severity on presentation (mean acute physiology and chronic health evaluation (APACHE) III scores, 111 ± 26 vs 74 ± 24), were more likely to have sepsis (84% vs 66%), and were more likely to be treated with vasopressors (79% vs 42%) compared to AKI-SP1.
Genetic Variation Near ANGPT2, rs2920656, is Associated with AKI-SP2
Of the 190 SNPs ±50 kilobases of the genes, 72 were near ANGPT1, 100 were near ANGPT2, and 18 were near the TNFRSF1A gene. We identified one SNP meeting an FDR < 0.05 that was associated with AKI-SP2 compared to AKI-SP1 (Table 2 and Fig. 1). No significant associations were observed with SNPs in or near ANGPT1 or TNFRSF1A (Table S2 and S3). The SNP demonstrating the strongest association with risk for AKI-SP2 was rs2920656 (OR, 0.45; 95% CI, 0.31–0.66; p < 1.4 × 10− 5 ; FDR = 0.003). This intronic SNP is ≈ 30 kb downstream to the 3′ position of ANGP T2 and explained approximately 3% of the variance in
the development of AKI-SP2 (R2 ). Because only a small number of subjects were homozygous rs2920656 (n = 26), we also tested associations between rs2920656 and AKI-SP2 in a dominant genetic model, which gave consistent results (OR, 0.42; 95% CI, 0.28–0.64; p < 1.4 × 10− 6 ). We also tested for additional, potentially stronger, associations within the ANGPT2 locus using imputed genotypes but did not find any associations stronger than that observed with rs2920656 (Table S4). In a sensitivity analysis, we tested whether the inclusion of critically ill patients without Acute kidney injury would influence the genetic association. We grouped patients with no AKI and AKI-SP1 together and determined whether rs2920656 was still strongly associated with a decreased risk of AKI-SP2. In this analysis, 839 patients had either no AKI or AKI-SP1 and 154 had AKI-SP2. The risk of developing AKI-SP2 again was significantly reduced with having at least one T allele for rs2920656 (OR 0.31; 95% CI, 0.19–0.52; p < 0.001) (Table S5). In another sensitivity analysis, we tested if rs2920656 was associated with decreased risk of AKI-SP2 within each of the four different studies that were included in iSPAAR. Within each of the three randomized control trials (ALTA, FACTT, and OMEGA) and the ICU prospective cohort (MEA), the point estimate was consistent with the minor allele of rs2920656 demonstrating a decreased risk for the development of AKI-SP2 (Table S6). Thus, rs2920656 was analyzed further to determine the association with plasma biomarker concentrations.
T allele of rs2920656 is associated with decreased plasma ANG-2
We next analyzed the association between rs2920656 and plasma ANG-2 concentrations. Adjusting for age, gender and sepsis each copy of the T allele of rs2920656 was associated with decreased log2 plasma ANG-2 concentrations (β = − 0.09; 95% CI -0.15, − 0.04; P = 0.002). Subjects homozygous for the C allele showed the highest concentrations of plasma ANG-2 (40,683 pg/ml; interquartile range (IQR) 19,374-73,205), while subjects homozygous for the T allele showed the lowest plasma ANG-2 concentrations (28,308 pg/ml (IQR 14,340-42, 944). In addition, of the 100 SNPs tested near the ANGP T2 gene region, rs29206565 was the most strongly associated with plasma ANG-2 concentrations (Fig. 2).
Mediation analysis suggests ANG-2 is causal in the development of AKI-SP2
We tested for evidence that the association between rs2920656 and risk for AKI-SP2 is mediated through plasma ANG-2 concentrations (Fig. 3). The total effect of rs2920656 on AKI-SP2 was βtotal = − 0.16 per allele (95% CI -0.24, − 0.10, p = 1.0 × 10− 4 ), which suggests that for each minor allele (T allele) of the genetic variant the risk of developing AKI-SP2 decreases by 16%. Causal mediation analysis detected a significant indirect effect for rs2920656 on AKI-SP2 that was mediated through plasma ANG-2 concentrations (βindirect, − 0.07 per allele; 95% CI -0.11, − 0.03; p = 0.001), which means the proportion of effect between rs2920656 and AKI-SP2 that is mediated by ANG-2 concentrations is 41.5%.
T allele of rs2920656 is associated with decreased AKI severity at 7 days
Next, we tested the association of rs2920656 with traditional criteria for AKI severity, such as maximum serum creatinine and increase in serum creatinine within 7 days after study enrollment. In a dominant genetic model, the T allele of rs2920656 was associated with a decrease in serum creatinine of − 0.44 mg/dL (95% CI, − 0.77, − 0.10), p = 0.01) after adjusting for age, gender, body mass index and sepsis status. The minor allele of rs2920656 was also associated with a decrease in the rise in serum creatinine between baseline and day 7 (β = − 0.25, 95% CI, − 0.46, − 0.03; p = 0.03)
T allele of rs2920656 is associated with lower ANG-2 in cell culture
We conducted in vitro experiments and in silico analyses to determine the functional significance of rs2920656. Of 8 different human fetal kidney tissue samples, 2 were CC, 5 were CT, and 1 was TT for rs2920656. In a dominant genetic model, ANG-2 concentrations were numerically greatest in endothelial cells from donors homozygous for the C allele and lower in carriers of the T allele, p = 0.07 (Fig. 4). In the GTEx project database, rs2920656 was not associated with ANGPT2 gene expression. However, two other SNPs (rs41311412 and rs2515591) that are in moderate LD (r2 = 0.23 and D’ = 0.86) with rs2920656 were associated with reduced ANGPT2 gene expression (p = 4.1 × 10− 5 ) in the tibial artery, a tissue which is highly enriched for endothelial cells (Table S7).
Plasma ANG-2 is minimally cleared by the kidneys To determine whether differences in kidney function could influence plasma ANG-2 concentrations, we measured ANG-2 renal clearance in critically ill subjects with and without AKI. In 20 different timed urine sample collections with bookended plasma samples, the median serum creatinine was 0.86 mg/dL with an interquartile range (IQR) of 0.69 to 1.45 mg/dL. The median plasma ANG-2 concentration was 10,261 pg/mL (IQR 6210–19,115 pg/mL). In contrast, urinary ANG-2 concentrations were 50-fold lower with a median of 206 pg/ mL (IQR 11–839 pg/mL). The calculated renal clearance of ANG-2 was < 1 mL/min for all timed urine collections, suggesting that plasma ANG-2 concentrations are not increased simply as a function of worsening AKI (Table 3)
